Oxair Chewable Tablet 4mg

Kraj: Malezja

Język: angielski

Źródło: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Składnik aktywny:

MONTELUKAST SODIUM

Dostępny od:

Y.S.P. INDUSTRIES (M) SDN BHD

INN (International Nazwa):

MONTELUKAST SODIUM

Sztuk w opakowaniu:

30Tablet Tablets; 100Tablet Tablets; 500Tablet Tablets

Wyprodukowano przez:

Y.S.P. INDUSTRIES (M) SDN BHD

Charakterystyka produktu

Manufacturer and Product Registration Holder:
Y.S.P. INDUSTRIES (M) SDN. BHD.
(192593 U)
Lot 3, 5 & 7, Jalan P/7, Section 13,
Kawasan Perindustrian Bandar Baru Bangi,
43000 Kajang, Selangor Darul Ehsan, Malaysia.
Ordering Line:1 800 88 3027
Product Info: 1 800 88 3679
R
5. Montelukast is a long term controller medication which should not
be
substituted for short-acting β-agonists. It is effective alone or in
combination
with other prophylactic agent.
6. Montelukast is a preventive agent, and can be added to the asthma
patient’s existing treatment regimen. Reduction in existing
treatment can be
made as tolerated.
7. With administration of montelukast, the dose of inhaled
corticosteroids can
be reduced gradually or even tapered off completely. However,
montelukast
should not be abruptly substituted for inhaled corticosteroids.
Orally administration
CONTRAINDICATIONS:
Hypersensitivity to any component of this product.
PRECAUTIONS / WARNINGS:
1. Montelukast should not be used to treat acute asthma attacks.
Patients
should be advised to have appropriate rescue medication available.
2. While the dose of concomitant inhaled corticosteroid may be reduced
gradually under medical supervision, Montelukast should not be
abruptly
substituted for inhaled or oral corticosteroids.
3. The reduction in systemic corticosteroid dose in patients receiving
anti-asthma agents including leukotriene receptor antagonists has been
followed in rare cases by the occurrence of one or more of the
following:
Eosinophilia,
vasculitic
rash,
worsening
pulmonary
symptoms,
cardiac
complications and/or neuropathy sometimes diagnosed as Churg-Strauss
Syndrome, a systemic eosinophilic vasculitis.
4. Patients with known aspirin sensitivity should continue avoidance
of aspirin
or nonsteroidal anti-inflammatory agents while taking Montelukast.
5. Safety and effectiveness in pediatric patients younger than 6
months of age
have not been studied.
6. Tablet of 4mg and 5mg contains aspartame therefore it is unsuitable
for
phenylketourics.
INTERACTION WITH O